Seven factors predict a delayed diagnosis of cardiac amyloidosis
暂无分享,去创建一个
M. Halushka | D. Judge | L. Barouch | E. Brown | Johana Fajardo | E. Bishop
[1] E. Miller,et al. Time Course of Common Clinical Manifestations in Patients with Transthyretin Cardiac Amyloidosis: Delay From Symptom Onset to Diagnosis. , 2018, Journal of cardiac failure.
[2] B. Reyes,et al. 021 - Carpal Tunnel Syndrome and Amyloid Cardiomyopathy , 2017 .
[3] A. Dispenzieri,et al. Light-chain cardiac amyloidosis: strategies to promote early diagnosis and cardiac response , 2017, Heart.
[4] M. Gertz,et al. Newer Therapies for Amyloid Cardiomyopathy , 2016, Current Heart Failure Reports.
[5] James C Moon,et al. Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis , 2016, Circulation.
[6] P. Kellman,et al. Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis , 2015, Circulation.
[7] E. González-López,et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. , 2015, European heart journal.
[8] R. Falk,et al. Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes. , 2015, Circulation. Heart failure.
[9] Yang Zhang,et al. Prognostic value of high-sensitivity cardiac troponin T in patients with endomyocardial-biopsy proven cardiac amyloidosis , 2014, Journal of geriatric cardiology : JGC.
[10] J. Leipsic,et al. Comparison of Al and Ttr Cardiac Amyloidosis: A Single Center Canadian Experience , 2013 .
[11] M. Lo Monaco,et al. TTR-related amyloid neuropathy: clinical, electrophysiological and pathological findings in 15 unrelated patients , 2013, Neurological Sciences.
[12] M. Halushka,et al. Relationship between monoclonal gammopathy and cardiac amyloid type. , 2013, Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology.
[13] F. Salvi,et al. Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective. , 2013, European heart journal.
[14] M. Lubberink,et al. In Vivo Visualization of Amyloid Deposits in the Heart with 11C-PIB and PET , 2013, The Journal of Nuclear Medicine.
[15] R. Falk,et al. Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS). , 2012, American heart journal.
[16] D. Dingli,et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] R. Falk,et al. Senile systemic amyloidosis presenting with heart failure: a comparison with light chain-associated amyloidosis. , 2005, Archives of internal medicine.
[18] M. Skinner,et al. A rare transthyretin mutation (Asp18Glu) associated with cardiomyopathy , 2004, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.
[19] T. Therneau,et al. Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins , 2003, The Lancet.
[20] J Ranstam,et al. Prevalence of carpal tunnel syndrome in a general population. , 1999, JAMA.
[21] R. Falk,et al. Familial and primary (AL) cardiac amyloidosis: echocardiographically similar diseases with distinctly different clinical outcomes. , 1997, Heart.
[22] G. Merlini,et al. Light Chain Amyloidosis: Patient Experience Survey from the Amyloidosis Research Consortium , 2015, Advances in Therapy.
[23] E. Boerwinkle,et al. The amyloidogenic V122I transthyretin variant in elderly black Americans. , 2015, The New England journal of medicine.